AlzeCure Pharma
1.96 SEK
0.00 %
Less than 1K followers
ALZCUR
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for AlzeCure Pharma
EV/EBIT
Median 2019-2021
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 3.53 | 7.80 | 5.12 | 3.71 | 2.79 | 1.09 | 2.00 |
| Shares | 43.9 | 43.9 | 43.9 | 56.6 | 69.3 | 92.9 | 114.9 |
| Market cap | 154.8 | 342.2 | 224.7 | 210.0 | 193.1 | 101.5 | 229.8 |
| Enterprise value | -27.7 | 229.7 | 183.0 | - | - | - | - |
| EV/S | - | - | - | - | - | - | - |
| EV/EBITDA | 0.5 | neg. | neg. | - | - | - | - |
| EV/EBIT | 0.5 | neg. | neg. | - | - | - | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 0.85 | 3.09 | 6.81 | 3.47 | 8.12 | 3.88 | 6.98 |
| P/S | - | - | - | - | - | - | - |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 97.5 % | 94.0 % | 72.2 % | 85.4 % | 74.3 % | 76.0 % | 55.8 % |
| Gearing ratio | - | - | - | - | - | - | 7.8 % |